Journal of Vascular Surgery
Volume 44, Issue 5 , Pages 971-975 , November 2006

Resource utilization in the treatment of critical limb ischemia: the effect of tissue loss, comorbidities, and graft-related events

Presented as a poster at the Thirty-fourth Annual Symposium of the Society for Clinical Vascular Surgery, Las Vegas, Nev, March 8-11, 2006.

  • Louis L. Nguyen, MD, MBA, MPH

      Affiliations

    • Division of Vascular and Endovascular Surgery, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass
    • Center for Surgery & Public Health, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass
    • Corresponding Author InformationReprint requests: Louis L. Nguyen, MD, MBA, MPH, Division of Vascular and Endovascular Surgery and the Center for Surgery & Public Health, Brigham & Women’s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115
    • ,
  • Stuart R. Lipsitz, ScD

      Affiliations

    • Center for Surgery & Public Health, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass
    • ,
  • Dennis F. Bandyk, MD

      Affiliations

    • Division of Vascular Surgery, University of South Florida, Tampa, Fla
    • ,
  • Alexander W. Clowes, MD

      Affiliations

    • Division of Vascular Surgery, University of Washington, Seattle, Wash
    • ,
  • Gregory L. Moneta, MD

      Affiliations

    • Division of Vascular Surgery, Oregon Health Sciences University, Portland, Ore
    • ,
  • Michael Belkin, MD

      Affiliations

    • Division of Vascular and Endovascular Surgery, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass
    • ,
  • Michael S. Conte, MD

      Affiliations

    • Division of Vascular and Endovascular Surgery, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass
    • Center for Surgery & Public Health, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass

Received 3 April 2006 ,Accepted 19 July 2006.

 Competition of interest: Drs Bandyk, Clowes, Moneta, Belkin, and Conte have each served as a paid consultant to Corgentech, Inc. Dr Conte has served as a paid consultant to Bristol-Myers Squibb. Dr Moneta owns stock in Bristol-Myers that predated the PREVENT III trial.

PII: S0741-5214(06)01360-7

doi: 10.1016/j.jvs.2006.07.035

Journal of Vascular Surgery
Volume 44, Issue 5 , Pages 971-975 , November 2006

Article Tools

* Image Usage & Resolution